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ABSTRACT
Background
To determine the origin of the neoplastic cell in central nervous system (CNS)
hemangioblastomas in von Hippel-Lindau disease (VHL) and its role in tumor formation and
distribution, we characterized and differentiated neoplastic cells from hemangioblastomas
removed from VHL patients.
Methods and Findings
A total of 31 CNS hemangioblastomas from 25 VHL patients were resected and analyzed.
Tumor cells from the hemangioblastomas were characterized, grown, and differentiated into
multiple lineages. Resected hemangioblastomas were located in the cerebellum (11 tumors),
brainstem (five tumors), and spinal cord (15 tumors). Consistent with an embryologically
derived hemangioblast, the neoplastic cells demonstrated coexpression of the mesodermal
markers brachyury, Flk-1 (vascular endothelial growth factor-2), and stem cell leukemia (Scl).
The neoplastic cells also expressed hematopoietic stem cell antigens and receptors including
CD133, CD34, c-kit, Scl, erythropoietin, and erythropoietin receptor. Under specific micro-
environments, neoplastic cells (hemangioblasts) were expanded and differentiated into
erythrocytic, granulocytic, and endothelial progenitors. Deletion of the wild-type VHL allele
in the hematopoietic and endothelial progeny confirmed their neoplastic origin.
Conclusions
The neoplastic cell of origin for CNS hemangioblastomas in VHL patients is the mesoderm-
derived, embryologically arrested hemangioblast. The hematopoietic and endothelial differ-
entiation potential of these cells can be reactivated under suitable conditions. These findings
may also explain the unique tissue distribution of tumor involvement.
The Editors’ Summary of this article follows the references.
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von Hippel-Lindau disease (VHL) is an autosomal domi-
nant neoplasia syndrome resulting from a germline mutation
in the VHL tumor suppressor gene on the short arm of
Chromosome 3 [1]. VHL has an approximate prevalence of
one in 39,000 and over 90% penetrance by 65 years of age
[2,3]. Germline mutations in the VHL gene lead to the
development of a number of benign or malignant tumors and
cysts in multiple organ systems [4]. Affected individuals may
develop central nervous system (CNS) tumors, including
hemangioblastomas and endolymphatic sac tumors [4–7].
Visceral manifestations include renal cysts and carcinomas,
pheochromocytomas, pancreatic cysts, and neuroendocrine
tumors, as well as epididymal and broad ligament cystadeno-
mas [4,8–10].
CNS hemangioblastomas are the most common tumor in
VHL, affecting 60%–80% of all patients, and are a frequent
cause of neurologic morbidity and mortality [4,7,11]. He-
mangioblastomas occur in highly deﬁned regions of the CNS
that include the retina, cerebellum, brainstem, and spinal
cord [4,7,11]. Histologically, hemangioblastomas are benign,
highly vascular tumors composed of neoplastic stromal cells
and vessels. Detailed morphologic analyses demonstrate
intratumoral blood island formation indicative of extrame-
dullary hematopoiesis [12,13].
Although the anatomic distribution and histologic features
of hemangioblastomas in VHL suggest they may be derived
from a developmental multipotent cell, the identity and
function of the cell of origin in hemangioblastomas remains
unknown. To determine the tumor cell of origin, the basis for
the unique CNS distribution of hemangioblastomas, and the
multipotent capability of hemangioblastomas in VHL, we
analyzed these tumors for embryologic and hematopoietic
stem cell markers. Based on the characterized features of
these tumors, we then derived hematopoietic and endothelial
progeny by microenvironment manipulation of resected
hemangioblastoma neoplastic cells.
Methods
Patients
Twenty-ﬁve VHL patients who underwent resection of a
CNS hemangioblastoma(s) between 2003 and 2005 at the NIH
were included. Patients were screened for the presence of
mutations and deletions of the VHL gene. All 25 patients met
the diagnostic criteria for VHL [4]. Patients underwent serial
craniospinal magnetic resonance imaging (MRI), and the
location of all imaged hemangioblastomas was recorded.
Research was performed under an institutional review board-
approved protocol (National Institute of Neurological Dis-
orders protocol 03-N-0164) and informed consent was
obtained from all patients.
Characterization of Hemangioblastomas
Frozen tumor sections were ﬁxed in methanol, washed in
PBS, and blocked with 5% serum (same species as the
secondary antibody) containing 0.2% Triton X-100. Slides
were stained with various antibodies overnight at 4 8C.
Staining antibodies included brachyury (10 lg/ml; R&D
Systems, http://www.rndsystems.com), Flk-1 (vascular endo-
thelial growth factor [VEGF] receptor-2) (15 lg/ml; R&D
Systems), stem cell leukemia (Scl) (1:100; Santa Cruz Bio-
technology, http://www.scbt.com), CD133 (1:10; Miltenyi Bio-
tec, http://www.miltenyibiotec.com), CD34 (1:100; Santa Cruz
Biotechnology), stem cell factor receptor (c-kit) (1:500;
DakoCytomation, http://www.dako.com), interleukin (IL)-3
receptor (1:50; Sigma, http://www.sigmaaldrich.com), erythro-
poietin (1:200; Sigma), and erythropoietin receptor (1:100;
Sigma). After washing in PBS, primary antibodies were
detected with AlexaFluor 488 and 555 secondary antibodies
(1:2,000; Molecular Probes, http://probes.invitrogen.com).
49,6-diamidino-2-phenylindole (DAPI) (300 nM; Molecular
Probes) was used for nuclear counterstaining. Incubation of
secondary antibodies without primary antibodies served as
negative controls.
To conﬁrm immunocytochemical ﬁndings, Western blot
analyses were performed. Protein extraction of hemangio-
blastoma tissue was performed by three cycles of freezing and
thawing of tumor tissue. Extracted protein was subjected to
4%–20% SDS–polyacrylamide gel (Invitrogen, http://www.
invitrogen.com) electrophoresis, transferred to nitrocellulose
membrane (Invitrogen), probed with brachyury antibody (0.2
lg/ml; R&D Systems), Scl antibody (1:200; Active Motif, http://
www.activemotif.com), Flk-1 (VEGF receptor-2) antibody (0.2
lg/ml; R&D Systems) and alpha-tubulin (positive control at
1:1,000; Sigma). Species-speciﬁc horseradish peroxidase-con-
jugated secondary antibody (1:30,000; Upstate, http://www.
upstate.com) was detected by enhanced chemiluminescence
substrate (Pierce Biotechnology, http://www.piercenet.com).
Cell Culture
Central cores of tumor from freshly resected VHL-
associated hemangioblastomas were excised. These cores
were rinsed in Hank’s balanced salt solution (Cambrex,
http://www.cambrex.com) and immediately placed in growth
medium (see description below). Single-cell suspensions of
tumors were established by manual trituration, enzymatic
digestion, and mechanical disaggregation (MediMachine;
Becton Dickinson, http://www.bdbiosciences.com). Contami-
nating red blood cells were removed by ACK cell lysing buffer
(Cambrex) and density-gradient centrifugation. The identity
of the isolated cells in suspension was determined by
analyzing aliquots for characteristic well-described morphol-
o g y ,h e m a t o x y l i na n de o s i ns taining, Giemsa staining,
immunocytochemistry, and/or loss of heterozygosity analyses.
Cells identiﬁed as hemangioblastoma tumor cells were placed
in wells coated with poly-L-ornithine (495 lg/ml; Sigma) and
ﬁbronectin (10 lg/ml; R&D Systems). The wells contained
alpha-MEM (Sigma) or RPMI (Gibco, http://www.invitrogen.
com) and were supplemented with fetal bovine serum (30%;
Cambrex), BSA (10%), beta-mercaptoethanol (0.1 lmol/l), L-
glutamine (1.5 mmol/l), penicillin (100 U/ml), streptomycin
(100 lg/ml), transferrin (120 lg/ml), selenium (6.7 ng/ml;
Gibco), insulin (10 lg/ml; Gibco), ferrous sulfate (900 ng/ml),
ferric nitrate (90 ng/ml), dexamethasone (0.01 lmol/l), stem
cell factor (100 ng/ml; R&D Systems) and erythropoietin (50–
100 U/ml; R&D Systems). Fresh medium was added every 3 d.
The tumor cells were resuspended and counted with a
hemacytometer every 3 d.
Differentiation of Hemangioblasts
Hematopoietic cells. Tumor cells were placed in plates and
dishes coated with poly-L-ornithine (495 lg/ml; Sigma) and
ﬁbronectin (10 lg/ml; R&D Systems). The cells were placed in
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Hemangioblastoma Originculture containing alpha-MEM (Sigma) and RPMI (Gibco)
supplemented with fetal bovine serum (30%; Cambrex), BSA
(10%), beta-mercaptoethanol (0.1 lmol/l), L-glutamine (1.5
mmol/l), penicillin (100 U/ml), streptomycin (100 lg/ml),
transferrin (120 lg/ml), selenium (6.7 ng/ml, Gibco), insulin
(10 lg/ml; Gibco), ferrous sulfate (900 ng/ml), ferric nitrate (90
ng/ml), insulin (10 lg/ml), dexamethasone (0.01 lmol/l), stem
cell factor (100 ng/ml; R&D Systems), erythropoietin (100 U/
ml; R&D Systems), IL-3 (10 ng/ml; R&D Systems) and GM-CSF
(10 ng/ml; R&D Systems), with and without G-CSF (50 ng/ml;
R&D Systems). Fresh medium was added every 3 d. Non-
adherent cells were resuspended and counted with a
hemacytometer every 3 d.
Endothelial cells. Tumor cells were placed in plates and
dishes coated with poly-L-ornithine (495 lg/ml; Sigma) and
ﬁbronectin (10 lg/ml; R&D Systems). The cells were placed in
culture containing IMDM (Gibco), fetal bovine serum (30%;
Cambrex), BSA (10%), L-glutamine (1.5 mmol/l), penicillin
(100 U/ml), streptomycin (100 lg/ml), transferrin (120 lg/ml),
selenium (6.7 ng/ml; Gibco), insulin (10 lg/ml, Gibco), VEGF (5
ng/ml; R&D Systems), stem cell factor (100 ng/ml; R&D
Systems), IGF-1 (10 ng/ml; R&D Systems), ﬁbroblast growth
factor-2 (10 ng/ml; R&D Systems), IL-11 (50 ng/ml; R&D
Systems), erythropoietin (15 U/ml, R&D Systems) and endo-
thelial cell growth supplement (100 lg/ml; Upstate). Fresh
medium was added every 3 d.
Nested Reverse Transcription Polymerase Chain Reaction
Cells morphologically consistent with a myeloid origin
were analyzed for the expression of CD13, a myeloid marker,
by nested reverse transcription PCR (RT-PCR) [14]. Brieﬂy,
total RNA was extracted and reverse-transcribed and
ampliﬁed by two rounds of PCR. Product of the second-
round PCR was electrophoresed on agarose gel and stained
with ethidium bromide.
Loss of Heterozygosity Analysis
Investigated tissues included uncultured tumor cells,
cultured tumor cells, cultured nucleated red blood cells,
cultured immature white blood cells, and cultured endothe-
lial cells. Peripheral blood-derived mononuclear cells from
patients served as a negative control. Speciﬁc cell types
(identiﬁed morphologically and immunohistochemically; as
described in text) were individually microdissected from
slides for DNA extraction [15], and analyzed by PCR for loss
of heterozygosity using the microsatellite markers D3S1038
and D3S1110 (Invitrogen) that ﬂank the VHL gene [13]. The
samples were electrophoresed on a polyacrylamide gel for
detection of the wild-type VHL allele.
Characterization of Cultured Cells
Hemangioblastoma tumor cells were harvested and applied
onto poly-D-lysine–coated slides by cytospin. Erythropoietin
and erythropoietin receptor immunostaining was performed
on tumor cells, as described above. Giemsa staining was
performed using modiﬁed Giemsa solution (1:10; Sigma).
Adherent cells were costained with Tie-2 (10 lg/ml; R&D
Systems) and CD31/PECAM-1 (5 lg/ml; R&D Systems) as
described above.
Results
Patient Characteristics
Twenty-ﬁve VHL patients (13 females, 12 males) underwent
resection of 31 CNS hemangioblastomas. Mean age at surgery
was 34.9 6 10.0 y (range 18–51 y). All patients had germline
mutations of the VHL gene. MRI revealed 244 craniospinal
hemangioblastomas distributed in the cerebellum (111
tumors; 45%), brainstem (14 tumors; 6%), and spinal cord
(115 tumors; 47%). There were four (2%) supratentorial
hemangioblastomas in the region of the pituitary stalk (three
tumors) and gyrus rectus (one tumor). Hemangioblastomas
that were removed and studied were from the cerebellum (11
tumors; 35% of tumors), brainstem (ﬁve tumors; 16%), or
spinal cord (15 tumors; 48%) (Figure 1).
Identification of Tumor Cell of Origin
All tumors were histologically conﬁrmed to be hemangio-
blastomas by routine staining. Immunoﬂuorescence micro-
scopy demonstrated that the hemangioblastoma neoplastic
Figure 1. Distribution of Hemangioblastomas in the Central Nervous
Systems of Study Patients
(A) Schematic representation of the distribution of CNS hemangioblas-
tomas (red dots) in the 25 von Hippel-Lindau disease patients on MRI.
Most (98%) of hemangioblastomas were found below the level of the
tentorium in the cerebellum, brainstem, and spinal cord.
(B–D) Contrast-enhanced MRI demonstrating representative locations of
hemangioblastomas including the cerebellum (B), brainstem (C) and
spinal cord (D). (B) Axial view through the cerebellum demonstrating a
hyperintense enhancing hemangioblastoma (arrow) with surrounding
edema (hypointense area surrounding the tumor) that frequently is
associated with these lesions. (C) Sagittal view through the posterior
fossa demonstrating a hyperintense enhancing brainstem (medullary)
hemangioblastoma (arrow) with surrounding edema. (D) Sagittal view
through the thoracic and lumbar spinal cord demonstrating two
hyperintense enhancing hemangioblastomas (arrows). The superior
tumor is associated with a large intraspinal cyst (syrinx) that is common
with these neoplasms (arrowhead).
doi:10.1371/journal.pmed.0040060.g001
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Hemangioblastoma Originstromal cells expressed the mesodermal marker brachyury.
Brachyury, a founding member of the T-box family of
transcription factors, has a conserved role in mesoderm
differentiation in vertebrates. Developmental studies indicate
that early speciﬁcation of posterior mesoderm and formation
of the notochord is regulated by brachyury [16]. Coexpression
of brachyury and Flk-1 (VEGF receptor-2) conﬁrmed that the
neoplastic cells were derived from the hemangioblast subset
of mesodermal cells (Figure 2). Flk-1 (VEGF receptor-2) is a
type 3 receptor tyrosine kinase that is believed to play a
critical role in developmental angiogenesis and hematopoi-
esis [17]. Expression of Scl, which is essential for both
primitive and deﬁnitive hematopoiesis, was demonstrated in
the tumors (Figure 2). Expression of these embryologic
markers was conﬁrmed by Western blot analysis (Figure 3).
Cellular Markers
To characterize the multipotent capacity of the hemangio-
blastoma neoplastic cells, we looked for expression of known
stem cell markers. Immunoﬂuorescence demonstrated ex-
pression of the stem cell marker CD133 (Figure 2C) and the
hematopoietic stem cell marker CD34 in a few scattered cells
throughout the hemangioblastomas. Similarly, c-kit and the
common myeloid antigen, IL-3 receptor, were expressed in
tumor cells in scattered regions throughout the hemangio-
blastomas. Coexpression of erythropoietin and erythropoie-
tin receptor was demonstrated throughout the tumors
(Figure 2D).
Primary Culture of Neoplastic Cells
At concentrations of 50 U/ml of erythropoietin or more,
hemangioblast cells were sustained and expanded in culture
(Figure 4). The identity of the cultured hemangioblasts, which
was conﬁrmed by morphology and immunoﬂuorescence,
demonstrated coexpression of erythropoietin and erythro-
poietin receptor. At culture concentrations of erythropoietin
at 100 U/ml, two other populations of nucleated cells
(nonadherent and adherent) appeared. The nonadherent
cells were identiﬁed by Giemsa staining as nucleated
erythrocyte or granulocyte progenitors in various stages of
differentiation (Figure 4). These hematopoietic progenitor
cells expanded over two weeks when the expansion stopped
and the absolute number of cells remained stable. Adherent
cells were identiﬁed as endothelial cells morphologically (ﬂat
and elongated) and by expression of endothelial markers Tie-
2 and CD31. These cells expanded beginning at two weeks
and continued to expand while in culture (at least 90 d).
Origin of Hematopoietic and Endothelial Progeny
To determine their origin, VHL gene deletion analyses
were performed on microdissected portions of uncultured
tumors, cultured tumor cells, cultured hematopoietic prog-
eny, and cultured endothelial progeny. Deletion of the wild-
type VHL allele (loss of heterozygosity) occurred in the
uncultured tumor specimens, cultured tumor cells, cultured
hematopoietic progeny, and cultured endothelial progeny,
conﬁrming their neoplastic origin (Figure 4). Peripheral
Figure 2. Immunofluorescent Characterization of the Neoplastic Stromal Cells in Hemangioblastoma Tissue Sections
(A) Neoplastic cells express the mesodermal marker, brachyury (green), Flk-1 (VEGF receptor-2; red), and the nuclear stain 49,6-diamidino-2-phenylindole
(DAPI) (blue). Coexpression of brachyury and Flk-1 (VEGF receptor-2) indicates that these cells are embryologic hemangioblasts.
(B) Expression of Scl (red) by the neoplastic cells indicates that these are hematopoietic stem cells committed to hematopoietic and endothelial
lineages.
(C) The neoplastic cells demonstrate scattered cytoplasmic expression of the hematopoietic stem cell antigen CD133 (red).
(D) Coexpression of the erythropoietin (green) and erythropoietin receptor (red) was uniformly demonstrated on the neoplastic cells.
doi:10.1371/journal.pmed.0040060.g002
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Hemangioblastoma Originblood–derived mononuclear cells from patients served as a
negative control (Figure 4).
Development and Expansion of Mature Hematopoietic
Progeny
To determine if the tumor-derived nonadherent immature
hematopoietic progenitors could be expanded into mature
erythrocytic or granulocytic progeny, we developed a culture
environment designed to expand immature hematopoietic
cells ex vivo that exploited the characterized receptor
expression (erythropoietin, IL3, and c-kit). In this environ-
ment, expansion of mature enucleated erythrocytes and
granulocytes occurred by day 3 with maximal proliferation
occurring by day 7. In vitro senescence of mature hemato-
logic progeny occurred beyond day 7. The mature eryth-
rocytes displayed characteristics similar to that of normal
erythrocytes, including a mean cell volume of 80.5 ﬂ, a mean
cell hemoglobin of 29.7 pg, and a mean corpuscular
hemoglobin concentration of 37 g/dl. The mature granulo-
cytes displayed characteristic morphology and the presence
of CD13 mRNA by RT-PCR.
Expansion of Endothelial Progeny
To expand the tumor-derived immature endothelial
progeny, we used a culture media designed to expand
immature endothelial cells ex vivo that exploited the
characterized receptor expression (erythropoietin, IL3, c-
kit, and Flk-1 [VEGF receptor-2]). The adherent endothelial
cells continued to proliferate while in culture (at least 30 d).
These expanded cells were adherent and morphologically
similar to endothelial cells (ﬂat and elongated). Consistent
with an endothelial lineage, these cells expressed the markers
Tie-2 and CD31 (Figure 5).
Discussion
Identiﬁcation of the cell of origin in tumors will improve
understanding of their pathobiology and treatment. For
familial tumor suppressor syndromes, it may also explain the
unique tissue distribution of tumor involvement. We found
that the neoplastic cells of origin in CNS hemangioblastomas
from VHL patients are derived from embryologically arrested
mesoderm cells and are hemangioblasts with hematopoietic
and vasculogenic (endothelial cell) potential. These cells
retain their multipotent differentiation ability and are able
to develop into hematopoietic and endothelial progenies.
The identiﬁcation of the cell of origin of this tumor enhances
understanding of the biological basis and tumor distribution
of this familial tumor suppressor syndrome and may provide
therapeutic opportunities.
Cell of Origin for Hemangioblastoma
From analysis of chick embryo development, Sabin (1920)
hypothesized the existence of a multipotent embryologic
precursor cell capable of forming both blood and vessels [18].
Based on Sabin’s hypothesis and the discovery of intra-
tumoral blood and vessel formation in CNS hemangioblasto-
Figure 3. Western Blot Analysis Confirms Expression of Hemangioblast Markers in Tumor Cells
Tumor samples (lanes 2 through 7) revealed expression of Flk-1 (VEGF receptor-2), Scl, and brachyury. Control (lane 1; normal brain) did not show
expression of these proteins.
doi:10.1371/journal.pmed.0040060.g003
Figure 4. Hematopoietic Progenies Are Derived from Hemangioblasto-
ma Tumor Cells
(A) Giemsa staining of the vacuolated neoplastic stromal cell of the
hemangioblastoma.
(B) Giemsa staining of early (arrows), late (arrowheads), and dividing
(open arrow) nucleated erythrocytes expanding in an erythropoietin-
enriched medium.
(C) Giemsa staining of immature (arrow) and mature (arrowhead)
polynuclear granulocytes expanding in an erythropoietin-enriched
medium.
(D) While loss of heterozygosity was not detected in peripheral blood
mononuclear cells (PB), deletion of the wild-type VHL allele occurred in
cultured hemangioblastoma (T) and cultured nucleated erythrocytes
(NE), confirming the hemangioblastic origin of the nucleated erythroid
cells.
doi:10.1371/journal.pmed.0040060.g004
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Hemangioblastoma Originmas, Stein et al. (1960) suggested that an arrested angiome-
senchymal cell or embryologic defect was the origin of these
tumors [12]. Based on embryonic stem cell lineage studies,
Choi et al. (1998) discovered the multipotent embryonic
precursor for both hematopoietic and endothelial cells that
Sabin had hypothesized, and deﬁned it as a ‘‘hemangioblast’’
[17]. Despite these observations, the histogenesis of heman-
gioblastomas has been unclear. It was only recently that
Vortmeyer et al. (1997) identiﬁed the stromal cell in
hemangioblastomas as the underlying neoplastic cell [19].
These previous ﬁndings and recent insights into the
molecular basis of embryologic development [16,20,21] and
tumor formation now permit investigation into the origin
and multipotent capability of the neoplastic cells in heman-
gioblastomas.
To investigate whether the cell of origin in hemangio-
blastomas is the embryologically arrested hemangioblast, we
characterized the neoplastic stromal cells from CNS heman-
gioblastomas derived from VHL patients. Consistent with a
cell of mesodermal origin, the neoplastic stromal cells in
these hemangioblastomas expressed the protein brachyury
[16]. Expression of brachyury, Flk-1 (VEGF receptor 2), and
Scl in the neoplastic stromal cells conﬁrm that the tumor
cell of origin in hemangioblastomas is an embryologic
hemangioblast [20]. Expression of Scl conﬁrms that these
are hematopoietic stem cells with self-renewal capabilities
and that they are committed to hematopoietic and endo-
thelial lineages [22–26]. These ﬁndings also indicate that
CNS hemangioblastomas are derived from committed
hematopoietic precursors and not a neurogenic progenitor,
as has been described with other primary CNS malignancies
[27,28].
Because brachyury is expressed only during early meso-
derm development [16], its expression in these neoplastic
cells suggests that VHL-related hemangioblastomas originate
from embryologically arrested mesodermal cells. This ﬁnding
has several potential implications for hemangioblastoma
development in VHL. First, it suggests that the precursor
cells (hemangioblasts) for hemangioblastoma formation are
present during embryologic development. Second, it also
implies that loss of the wild-type allele, which is necessary for
hemangioblastoma formation in VHL [29], occurs during
embryogenesis. Third, these observations indicate that VHL
tumor suppressor gene function affects development. These
ﬁndings are consistent with previous studies that demon-
strate that loss of tumor suppressor gene function can affect
normal tissue development [30–32]. Recently, Zhu et al. [33]
found that mice genetically engineered to lack the neuro-
ﬁbromatosis-1 tumor suppressor gene demonstrated a variety
of developmental defects that resulted in increased prolifer-
ation of glial progenitors cells, which in some cases led to
optic nerve glioma formation (part of the neuroﬁbromatosis-
1 neoplasia phenotype). Fourth, an embryologically arrested
hemangioblast may explain the presence of fetal hemoglobin
within blood islands of resected hemangioblastomas from
VHL patients [13,34]. Finally, these data support an emerging
concept of tumor formation during development in a variety
of different tumor types. Speciﬁcally, Trichopoulos et al. [35]
has hypothesized a perinatal site-speciﬁc increase in stem
cells as an underlying mechanism of breast cancer develop-
ment and Samuelson et al. [36] found that increased head
circumference was positively correlated with the incidence of
childhood brain cancer, implying that pathogenesis occurs
during fetal life.
Development of Hematopoietic and Endothelial Progeny
To determine if the hemangioblasts in hemangioblastomas
have the same multipotent developmental capacity (hema-
topoietic and endothelial) as hemangioblasts during embryo-
logic development, we further characterized these cells and
analyzed their capacity for multilineage differentiation.
Tumors were characterized by scattered expression of
hematopoietic stem cell markers CD133 and CD34, as well
as stem cell factor receptor (c-kit) and IL-3 receptor. Based on
the uniform expression of erythropoietin and erythropoietin
receptor by the hemangioblasts, suggesting a neoplastic
erythropoietin-driven autocrine loop [13,37], we initially
cultured the neoplastic cells in an erythropoietin-enriched
media. Similar to embryologic hemangioblasts, hemangio-
blastoma-derived hemangioblasts demonstrated self-renewal
Figure 5. Endothelial Progeny Derive from Hemangioblastoma Tumor
Cells
(A) Differential interference contrast image of adherent cells derived
from cultured hemangioblasts. Note the flat, elongated morphology
similar to endothelial cells.
(B) These cells expressed the endothelial markers Tie-2 (red), and CD31
(green) (nuclear stain 49,6-diamidino-2-phenylindole; blue).
doi:10.1371/journal.pmed.0040060.g005
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Hemangioblastoma Originand differentiated into hematopoietic (erythroid and mye-
loid) and endothelial lineages in this environment. These
ﬁndings are in agreement with observations in other tumors
in which stem cells have been proposed as the origin of tumor
initiation and propagation [27,38–41].
According to Knudson’s ‘‘two-hit’’ hypothesis of tumori-
genesis [42], initiation of tumor formation follows inactiva-
tion of both alleles of the VHL gene. Because germline
mutations of the VHL gene were present in all of these
patients. and deletion of the remaining wild-type allele is
necessary to develop VHL-associated tumors (i.e., hemangio-
blastomas), we were able to conﬁrm the origin of the
hematopoietic and endothelial progeny by loss of hetero-
zygosity analyses. Deletion of the wild-type VHL allele (loss of
heterozygosity) was found in the cultured hematopoietic and
endothelial progeny, conﬁrming their neoplastic origin.
The functional ability of the hemangioblast-derived im-
mature hematopoietic progenitors to expand into mature
erythrocytic and granulocytic progeny was tested using a
culture media designed to expand immature hematopoietic
cells ex vivo [14] and to exploit the characterized receptor
expression (erythropoietin receptor, c-kit, and IL-3). The
capacity of the hemangioblast-derived endothelial progeni-
tors to proliferate in a manner similar to early vasculogenesis
was examined using a different culture medium designed to
generate endothelial cells ex vivo and that also exploited the
characterized receptor expression (erythropoietin receptor
and Flk-1 [VEGF receptor-2]) [17]. As occurs with extra-
medullary hematopoiesis and blood island formation, ex-
pansion of mature enucleated erythrocytes and endothelial
cells occurred in these environments. These ﬁndings are
consistent with the presence of a developmentally arrested
hemangioblast that can be functionally reactivated under
appropriate environmental conditions and concur with
histological evidence of intratumoral blood island formation
in hemangioblastomas [12,13].
Implications for Clinical Development of
Hemangioblastomas
While our ﬁndings indicate that the cell of origin for VHL-
associated hemangioblastomas are established during devel-
opment, clinically signiﬁcant or radiographic-evident heman-
gioblastomas rarely occur in infancy or early childhood in
VHL. This observation is consistent with the known tendency
of these tumors for slow growth and well-documented
quiescent growth periods that can last for years [11,43]. Thus,
it is likely that in early childhood many of these tumors
remain asymptomatic and below the level of radiographic
detection (even by sensitive MRI techniques). An analogous
situation is the presence of endolymphatic sac tumors, which
are undetectable by imaging for years in many patients with
VHL [5,6,44].
The presence of subclinical and infraradiologic hemangio-
blastoma tumorlets in VHL patients at autopsy supports the
concept that these tumors may be developmentally arrested
but reactivated under appropriate conditions later in life
[34]. There are several factors that could conceivably be
involved in the propagation of these tumors. Circulating
factors, including hormones (e.g., during puberty or preg-
nancy) could promote the growth of previously transformed
tumor cells [45–47]. Similarly, local microenvironmental
stimuli driven by autocrine or paracrine loops have been
hypothesized to spur hemangioblastoma growth [13]. Finally,
additional genetic alterations could underlie the observed
delayed appearance and erratic growth of these tumors.
Implications for the Distribution of Hemangioblastomas
Because embryologic development results in the precise
topographical arrangement of various cell types, a hemangio-
blast-deﬁned origin of hemangioblastomas could explain the
distribution of these tumors. We recently examined the
natural history and location of CNS hemangioblastomas (655
CNS hemangioblastomas in 160 consecutive patients) in VHL
patients as deﬁned by MRI [11]. Consistent with the
distribution of hemangioblastomas found here, that study
revealed that hemangioblastomas were found only within
very deﬁned regions of the CNS, including the cerebellum
(38%), brainstem (10%), and spinal cord (51%).
This tumor distribution coincides with previous topo-
graphical analyses, which revealed that Scl is transiently
expressed by embryologic hemangioblast cells during devel-
opment in the retina, diencephalon, mesencepahlon, meten-
cephalon, and spinal cord, but not the telencephalon
[22,24,48–50]. Thus, the highly speciﬁc distribution of Scl
gene expression during embryogenesis correlates with the
restricted distribution of hemangioblastomas in VHL pa-
tients [11]. The rare occurrence (less than 1%) of hemangio-
blastomas in the supratentorial cerebral hemispheres may
represent an ectopic rest of hemangioblasts. Taken together,
these ﬁndings suggest that hemangioblastoma distribution in
VHL does not result from migration of the tumor-initiating
cells (hemangioblast); instead, developmental processes may
govern distribution. The topographic and tissue-restricted
distribution patterns of tumors that occur in other familial
neoplasia syndromes may also arise by a similar mechanism.
Study Limitations
Because we examined only VHL-associated hemangioblas-
tomas, the results of this study may not be applicable to
hemangioblastomas that arise sporadically. Moreover, be-
cause hemangioblastomas are benign neoplasms, these ﬁnd-
ings may not apply to malignant tumors, particularly those
that do not arise in the context of tumor suppressor
syndromes. Future analyses of other malignant tumors may
be necessary to understand the factors involved with growth
initiation, clinical development, and the developmental
effects of tumor suppressor genes.
Potential Clinical Implications
Several ﬁndings of this study may have future implications
for clinical practice. The data here support the concept of a
multipotent tumor stem cell as the initiating and sustaining
cell in hemangioblastomas in the context of VHL. Speciﬁ-
cally, an embryologically arrested hemangioblast that retains
the ability to form blood and endothelial cells appears to
underlie the formation and propagation of benign VHL-
associated hemangioblastomas. Identiﬁcation of the heman-
gioblast as the cell of origin in hemangioblastomas could
permit the selective targeting of uniquely expressed proteins
or modulation of speciﬁc molecular pathways in the selective
treatment of these neoplasms. Moreover, strategies that
exploit the known differentiation potential (blood and
endothelial cells) of the hemangioblast may offer an alter-
native treatment paradigm.
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These ﬁndings indicate that the neoplastic cells from CNS
hemangioblastomas from VHL patients are hemangioblasts
derived from embryologically arrested mesoderm. These
embryologic tumor cells retain their multipotent differ-
entiation ability and can develop into hematopoietic or
endothelial progeny. The identiﬁcation of the cell of origin of
this tumor enhances understanding of the biological basis of
this familial tumor suppressor syndrome and may provide
therapeutic opportunities.
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Editors’ Summary
Background. von Hippel-Lindau (VHL) disease is a rare genetic condition
characterized by the development of benign and malignant tumors in
multiple organ systems. All the cells of people with this disorder contain
one normal copy of the VHL gene and one altered copy. This gene
encodes a tumor suppressor, a protein that stops tumors growing. One
functioning copy of the VHL gene is sufficient to prevent any problems,
but if the remaining normal copy becomes altered (mutated) in
individual cells of patients with VHL disease, tumors result. These tumors
are mainly benign (noncancerous growths that do not spread around the
body) and form in parts of the body that are rich in blood vessels, in
particular in the retina (the back of the eye), the cerebellum (the back of
the brain), the brainstem (which links the cerebellum to the spinal cord),
and the spinal cord. These central nervous system (CNS) tumors are
called hemangioblastomas and look like little knots of capillaries (fine
blood vessels). As they grow, they can cause problems through fluid
leakage or by pressing on brain tissue. There is no cure for VHL disease,
but patients can be monitored and their tumors dealt with before they
get too large.
Why Was This Study Done? It is not known what sort of cells
hemangioblastomas develop from or why they occur only in specific
parts of the CNS. This information could help researchers develop ways
to prevent or treat these hemangioblastomas. One possibility is that
hemangioblastomas develop from a special kind of embryonic cell called
a hemangioblast. This multipotent stem cell—a continuously dividing
cell that can develop (differentiate) into several nondividing cell types—
is the source of blood cells and blood vessel cells in the embryo. In this
study, the researchers have examined tumor cells (so-called neoplastic
stromal cells) taken from hemangioblastomas to see whether this theory
is correct.
What Did the Researchers Do and Find? The researchers obtained
several CNS hemangioblastomas from patients with VHL disease and
stained slices of them with antibodies that stick to proteins made only by
specific types of embryonic cells. This experiment showed that the
neoplastic stromal cells in the tumors contained two proteins (brachyury
and Flk-1) that mark hemangioblast cells in embryos and a protein called
Scl that is required for blood cell formation. The neoplastic stromal cells
also made several proteins expressed by the precursors of different
blood cell types. When the researchers grew neoplastic stromal cells
from the hemangioblastomas in different conditions, they found that the
cells differentiated into the precursors of two types of blood cell
(erythrocytes and granulocytes) and of the cells that line blood vessels
(endothelial cells). The researchers confirmed that these precursors had
arisen from the neoplastic cells in the hemangioblastomas by showing
that they did not contain a normal copy of the VHL gene.
What Do These Findings Mean? These findings indicate that the
neoplastic stromal cells in CNS hemangioblastomas in patients with VHL
disease are indeed hemangioblasts. Their expression of the protein
brachyury, which is normally only expressed in early development,
suggests that these hemangioblasts were arrested during embryo-
genesis, possibly when they lost their normal VHL gene. Because VHL-
related tumors usually appear in adulthood, circulating factors such as
hormones might promote the growth of these pre-existing but dormant
tumor cells at specific stages of life. Furthermore, the expression of Scl in
the neoplastic stromal cells suggests that the specific pattern of
hemangioblastomas in VHL disease is determined during development
since Scl is transiently expressed in hemangioblasts in the parts of the
developing brain that subsequently harbor hemangioblastomas. Because
the researchers only examined VHL-associated hemangioblastomas, their
findings do not explain the origin of hemangioblastomas in patients
without VHL disease or the origin of VHL-associated malignant tumors.
However, the identification of hemangioblasts as the source of
hemangioblastomas in VHL disease suggests that it might be possible
to treat these tumors by persuading the hemangioblasts to differentiate
or by using their unique proteins to target toxic drugs to hemangio-
blastomas.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/doi:10.1371/journal.pmed.
0040060.
 VHL Family Alliance has information for patients and physicians on
VHL disease
 The US National Institute of Neurological Disorders and Stroke Web
site contains information on VHL disease
 Wikipedia carries pages on VHL disease (note that Wikipedia is a free
online encyclopedia that anyone can edit)
 The Online Mendelian Inheritance in Man (OMIM) site has detailed
scientific information on VHL disease
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